Roosevelt Island, NY, United States of America

Till Milde

This inventor holds 1 USPTO granted patent. Top assignee: Cornell University. Active years: 2011.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Till Milde. Retrieved from https://idiyas.com/inventor/till-milde

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

% Patents Active = 100.0

Average Co-Inventor Count = 3.0

ph-index = 1


Company Filing History:


Years Active: 2011

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovative Contributions of Till Milde

Introduction

Till Milde is a notable inventor based in Roosevelt Island, NY (US). He has made significant contributions to the field of stem cell research through his innovative patent. His work focuses on the use of slitrk proteins as markers for stem and progenitor cells, which has important implications for medical research and treatment.

Latest Patents

Till Milde holds a patent titled "Slitrks as markers for stem and progenitor cells and methods of use thereof." This invention relates to slitrk proteins as markers of stem and progenitor cells, including embryonic stem cells and hematopoietic stem and progenitor cells. Additionally, it serves as a marker for leukemia and lymphoma cells, as well as endothelial cells. The patent provides various methods for purifying slitrk-positive cells, detecting these cells, and creating therapeutic compositions that include purified slitrk-positive cells. Furthermore, it outlines methods for targeting therapeutic agents to slitrk-positive cells and administering these cells to subjects in need.

Career Highlights

Till Milde is affiliated with Cornell University, where he continues to advance his research in the field of stem cell biology. His work has garnered attention for its potential to improve treatment options for various diseases, including cancer.

Collaborations

Some of Till Milde's notable coworkers include Sergey V Shmelkov and Shahin Rafii. Their collaborative efforts contribute to the ongoing research and development in the field of stem cell therapies.

Conclusion

Till Milde's innovative work in identifying slitrk proteins as markers for stem and progenitor cells represents a significant advancement in medical research. His contributions have the potential to enhance therapeutic strategies for treating serious health conditions.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…